IL293705A - Antibodies for the treatment of chronic graft-versus-host disease - Google Patents

Antibodies for the treatment of chronic graft-versus-host disease

Info

Publication number
IL293705A
IL293705A IL293705A IL29370522A IL293705A IL 293705 A IL293705 A IL 293705A IL 293705 A IL293705 A IL 293705A IL 29370522 A IL29370522 A IL 29370522A IL 293705 A IL293705 A IL 293705A
Authority
IL
Israel
Prior art keywords
csf
antibody
dose
axatilimab
patients
Prior art date
Application number
IL293705A
Other languages
English (en)
Hebrew (he)
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of IL293705A publication Critical patent/IL293705A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL293705A 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft-versus-host disease IL293705A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945842P 2019-12-09 2019-12-09
US202063110111P 2020-11-05 2020-11-05
PCT/US2020/064010 WO2021119128A1 (en) 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft versus host disease

Publications (1)

Publication Number Publication Date
IL293705A true IL293705A (en) 2022-08-01

Family

ID=76330540

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293705A IL293705A (en) 2019-12-09 2020-12-09 Antibodies for the treatment of chronic graft-versus-host disease

Country Status (11)

Country Link
US (1) US12552869B2 (https=)
EP (1) EP4073100A4 (https=)
JP (1) JP2023506779A (https=)
KR (1) KR20220123004A (https=)
CN (1) CN115298210A (https=)
AU (1) AU2020401551A1 (https=)
CA (1) CA3164126A1 (https=)
IL (1) IL293705A (https=)
MX (1) MX2022007029A (https=)
PH (1) PH12022551401A1 (https=)
WO (1) WO2021119128A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260013464A (ko) * 2023-05-17 2026-01-28 신닥스 파마슈티컬스, 인크. 항-콜로니 자극 인자 1 수용체 항체를 이용한 만성 이식편대숙주 질환-관련 폐쇄성 세기관지염 증후군의 치료 방법
CN121620392A (zh) * 2023-07-23 2026-03-06 因赛特公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病的方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JP2008526773A (ja) * 2004-12-30 2008-07-24 ドール バイオファーマ、インコーポレイテッド ベクロメタゾンジプロピオネート及びプレドニゾンでの、移植片対宿主病及び白血病の治療
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
EP2076266A2 (en) 2006-05-31 2009-07-08 The Board of Trustees of the Leland Stanford Junior University Method of treating inflammatory diseases using tyroskine kinase inhibitors
WO2008055013A2 (en) 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
PL2188313T3 (pl) 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI0909044B8 (pt) 2008-03-14 2021-05-25 Transgene Sa anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
UA112425C2 (uk) 2010-12-13 2016-09-12 Еррей Біофарма Інк. ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
ES2763309T3 (es) 2015-02-09 2020-05-28 UCB Biopharma SRL Formulación farmacéutica que comprende anticuerpos
CN111278459A (zh) * 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法

Also Published As

Publication number Publication date
EP4073100A1 (en) 2022-10-19
KR20220123004A (ko) 2022-09-05
US12552869B2 (en) 2026-02-17
PH12022551401A1 (en) 2023-08-23
WO2021119128A1 (en) 2021-06-17
MX2022007029A (es) 2022-08-15
CA3164126A1 (en) 2021-06-17
JP2023506779A (ja) 2023-02-20
AU2020401551A1 (en) 2022-06-30
EP4073100A4 (en) 2024-02-14
CN115298210A (zh) 2022-11-04
US20230035183A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
CN110382545A (zh) 用抗pd-1抗体治疗癌症的方法
US20250064925A1 (en) Method of treating cancer using a combination of entinostat and an anti-csf-1r antibody
AU2019361247B2 (en) Method for the treatment of Myasthenia Gravis
WO2018183366A1 (en) Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
US20230131598A1 (en) Combination treatment for cancer
US12552869B2 (en) CSF-1R antibodies for the treatment of chronic graft versus host disease
US20230140694A1 (en) Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
KR102628314B1 (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
EA052089B1 (ru) Антитела для лечения хронического заболевания "трансплантат против хозяина"
WO2025085792A1 (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
HK40109234A (zh) 用於治疗癌症的方法和组合物
JP2023504679A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して扁平苔癬を治療する方法